Biomarkers /
KRAS
Back to Biomarkers List
Overview
KRAS (Kirsten rat sarcoma viral oncogene homolog) encodes for the GTPase KRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. KRAS is implicated in the pathogenesis of several cancers.
Biomarker-Directed Therapies
KRAS is a predictive biomarker for use of cetuximab, panitumumab, afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, and sotorasib in patients.
Non-small cell lung carcinoma and colorectal carcinoma have the most therapies with KRAS as a predictive biomarker.
Of the therapies with KRAS as a predictive biomarker, 3 are FDA-approved in at least one clinical setting and 7 have NCCN guidelines in at least one clinical setting.
KRAS G12C, KRAS Mutation, KRAS G12S, KRAS A11_G12dup, and KRAS A146P are the top alterations on KRAS targeted by therapies [4].
Afatinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Cetuximab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: Preclinical studies and limited retrospective data suggest that KRAS amplification confers resistance to anti-EGFR antibodies. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Osimertinib +
Non-Small Cell Lung Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Panitumumab +
Colorectal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Resistance |
| Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (NCCN) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Resistance |
| Clinical Setting(s): Metastatic (MCG) | |
| Note: Preclinical studies and limited retrospective data suggest that KRAS amplification confers resistance to anti-EGFR antibodies. |
Sotorasib +
Non-Small Cell Lung Carcinoma -
Clinical Trials
KRAS status serves as an inclusion eligibility criteria in 195 clinical trials, of which 147 are open and 48 are closed. Of the trials that contain KRAS status as an inclusion criterion, 2 are early phase 1 (2 open), 75 are phase 1 (51 open), 48 are phase 1/phase 2 (39 open), 61 are phase 2 (46 open), and 9 are phase 3 (9 open).
Trials with KRAS status in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, malignant solid tumor, colorectal carcinoma, colorectal adenocarcinoma, and acute myeloid leukemia [4].
The most frequent alterations to serve as inclusion eligibility criteria are KRAS Mutation, KRAS G12C, KRAS Codon 12 Missense, and KRAS Codon 13 Missense [4].
Trametinib, pembrolizumab, binimetinib, docetaxel, and selumetinib are the most frequent therapies in trials with KRAS as an inclusion criteria [4].
Significance of KRAS in Diseases
Non-Small Cell Lung Carcinoma +
KRAS is an inclusion criterion in 73 clinical trials for non-small cell lung carcinoma, of which 57 are open and 16 are closed. Of the trials that contain KRAS status and non-small cell lung carcinoma as inclusion criteria, 34 are phase 1 (26 open), 15 are phase 1/phase 2 (13 open), 19 are phase 2 (13 open), and 5 are phase 3 (5 open) [4].
Sotorasib has evidence of efficacy in patients with KRAS mutation in non-small cell lung carcinoma [4].
Malignant Solid Tumor +
KRAS is an inclusion criterion in 74 clinical trials for malignant solid tumor, of which 51 are open and 23 are closed. Of the trials that contain KRAS status and malignant solid tumor as inclusion criteria, 41 are phase 1 (26 open), 23 are phase 1/phase 2 (18 open), and 10 are phase 2 (7 open) [4].
Colorectal Carcinoma +
KRAS is an inclusion criterion in 44 clinical trials for colorectal carcinoma, of which 32 are open and 12 are closed. Of the trials that contain KRAS status and colorectal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 25 are phase 1 (18 open), 11 are phase 1/phase 2 (9 open), 6 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Acute Myeloid Leukemia +
KRAS is an inclusion criterion in 13 clinical trials for acute myeloid leukemia, of which 8 are open and 5 are closed. Of the trials that contain KRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 4 are phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [4].
Colorectal Adenocarcinoma +
KRAS is an inclusion criterion in 12 clinical trials for colorectal adenocarcinoma, of which 10 are open and 2 are closed. Of the trials that contain KRAS status and colorectal adenocarcinoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 6 are phase 2 (6 open), and 2 are phase 3 (2 open) [4].
Melanoma +
KRAS is an inclusion criterion in 12 clinical trials for melanoma, of which 9 are open and 3 are closed. Of the trials that contain KRAS status and melanoma as inclusion criteria, 9 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Pancreatic Carcinoma +
KRAS is an inclusion criterion in 12 clinical trials for pancreatic carcinoma, of which 9 are open and 3 are closed. Of the trials that contain KRAS status and pancreatic carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [4].
Breast Carcinoma +
KRAS is an inclusion criterion in 10 clinical trials for breast carcinoma, of which 6 are open and 4 are closed. Of the trials that contain KRAS status and breast carcinoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (0 open) [4].
Myelodysplastic Syndromes +
KRAS is an inclusion criterion in 9 clinical trials for myelodysplastic syndromes, of which 6 are open and 3 are closed. Of the trials that contain KRAS status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [4].
Ovarian Carcinoma +
KRAS is an inclusion criterion in 8 clinical trials for ovarian carcinoma, of which 5 are open and 3 are closed. Of the trials that contain KRAS status and ovarian carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [4].
Chronic Myelomonocytic Leukemia +
KRAS is an inclusion criterion in 7 clinical trials for chronic myelomonocytic leukemia, of which 5 are open and 2 are closed. Of the trials that contain KRAS status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [4].
Lung Adenocarcinoma +
KRAS is an inclusion criterion in 7 clinical trials for lung adenocarcinoma, of which 7 are open and 0 are closed. Of the trials that contain KRAS status and lung adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [4].
Pancreatic Ductal Adenocarcinoma +
KRAS is an inclusion criterion in 7 clinical trials for pancreatic ductal adenocarcinoma, of which 5 are open and 2 are closed. Of the trials that contain KRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 5 are phase 1 (4 open) and 2 are phase 1/phase 2 (1 open) [4].
Squamous Cell Lung Carcinoma +
KRAS is an inclusion criterion in 7 clinical trials for squamous cell lung carcinoma, of which 4 are open and 3 are closed. Of the trials that contain KRAS status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (1 open) [4].
Non-Hodgkin Lymphoma +
KRAS is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 4 are open and 2 are closed. Of the trials that contain KRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [4].
Pancreatic Adenocarcinoma +
KRAS is an inclusion criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS status and pancreatic adenocarcinoma as inclusion criteria, 4 are phase 1 (4 open) and 2 are phase 1/phase 2 (2 open) [4].
Cancer +
KRAS is an inclusion criterion in 5 clinical trials for cancer, of which 3 are open and 2 are closed. Of the trials that contain KRAS status and cancer as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [4].
Endometrial Carcinoma +
KRAS is an inclusion criterion in 5 clinical trials for endometrial carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 1/phase 2 (3 open) [4].
Head And Neck Squamous Cell Carcinoma +
KRAS is an inclusion criterion in 5 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 2 are closed. Of the trials that contain KRAS status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].
Multiple Myeloma +
KRAS is an inclusion criterion in 5 clinical trials for multiple myeloma, of which 4 are open and 1 is closed. Of the trials that contain KRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].
Bladder Carcinoma +
KRAS is an inclusion criterion in 4 clinical trials for bladder carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS status and bladder carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [4].
Esophageal Carcinoma +
KRAS is an inclusion criterion in 4 clinical trials for esophageal carcinoma, of which 2 are open and 2 are closed. Of the trials that contain KRAS status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [4].
Hepatocellular Carcinoma +
KRAS is an inclusion criterion in 4 clinical trials for hepatocellular carcinoma, of which 4 are open and 0 are closed. Of the trials that contain KRAS status and hepatocellular carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Acute Lymphoblastic Leukemia +
KRAS is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].
Cholangiocarcinoma +
KRAS is an inclusion criterion in 3 clinical trials for cholangiocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].
Colon Carcinoma +
KRAS is an inclusion criterion in 3 clinical trials for colon carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [4].
Gastric Carcinoma +
KRAS is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and gastric carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (0 open) [4].
Gastrointestinal Stromal Tumor +
KRAS is an inclusion criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 1 is open and 2 are closed. Of the trials that contain KRAS status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Glioblastoma +
KRAS is an inclusion criterion in 3 clinical trials for glioblastoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS status and glioblastoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [4].
Glioma +
KRAS is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and glioma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].
Neurofibromatosis Type 1 +
KRAS is an inclusion criterion in 3 clinical trials for neurofibromatosis type 1, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and neurofibromatosis type 1 as inclusion criteria, 3 are phase 2 (2 open) [4].
Non-Squamous Non-Small Cell Lung Carcinoma +
KRAS is an inclusion criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [4].
Prostate Carcinoma +
KRAS is an inclusion criterion in 3 clinical trials for prostate carcinoma, of which 1 is open and 2 are closed. Of the trials that contain KRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [4].
Renal Cell Carcinoma +
KRAS is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and renal cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Thyroid Gland Carcinoma +
KRAS is an inclusion criterion in 3 clinical trials for thyroid gland carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
KRAS is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 2 are closed. Of the trials that contain KRAS status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (0 open) [4].
Ampulla Of Vater Carcinoma +
KRAS is an inclusion criterion in 2 clinical trials for ampulla of vater carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and ampulla of vater carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].
Cutaneous Melanoma +
KRAS is an inclusion criterion in 2 clinical trials for cutaneous melanoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and cutaneous melanoma as inclusion criteria, 2 are phase 1 (2 open) [4].
Diffuse Large B-Cell Lymphoma +
KRAS is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].
Head And Neck Carcinoma +
KRAS is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and head and neck carcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].
Histiocytic And Dendritic Cell Neoplasm +
KRAS is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [4].
Juvenile Myelomonocytic Leukemia +
KRAS is an inclusion criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 2 (1 open) [4].
Low Grade Glioma +
KRAS is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].
Low Grade Ovarian Serous Adenocarcinoma +
KRAS is an inclusion criterion in 2 clinical trials for low grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Lymphoma +
KRAS is an inclusion criterion in 2 clinical trials for lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].
Myelodysplastic Syndrome With Excess Blasts-2 +
KRAS is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].
Poorly Differentiated Thyroid Gland Carcinoma +
KRAS is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Secondary Acute Myeloid Leukemia +
KRAS is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Small Cell Lung Carcinoma +
KRAS is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Therapy-Related Acute Myeloid Leukemia +
KRAS is an inclusion criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +
KRAS is an inclusion criterion in 2 clinical trials for thyroid gland undifferentiated (anaplastic) carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Urothelial Carcinoma +
KRAS is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +
KRAS is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].
Adenocarcinoma +
KRAS is an inclusion criterion in 1 clinical trial for adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Adenosquamous Lung Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for adenosquamous lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and adenosquamous lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Anal Canal Squamous Cell Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for anal canal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and anal canal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Anaplastic Astrocytoma +
KRAS is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Astrocytic Tumor +
KRAS is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
B-Cell Acute Lymphoblastic Leukemia +
KRAS is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Biliary Tract Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Breast Adenocarcinoma +
KRAS is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and breast adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Cervical Squamous Cell Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Chordoma +
KRAS is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and chordoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Chronic Myeloid Leukemia +
KRAS is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Clear Cell Renal Cell Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Diffuse Glioma +
KRAS is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Double-Hit Lymphoma +
KRAS is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].
Dysembryoplastic Neuroepithelial Tumor +
KRAS is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Embryonal Rhabdomyosarcoma +
KRAS is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Esophageal Squamous Cell Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Gallbladder Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Gangliocytoma +
KRAS is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Ganglioglioma +
KRAS is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Gastric Adenocarcinoma +
KRAS is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].
Germ Cell Tumor +
KRAS is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
KRAS is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Kidney Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for kidney carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and kidney carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].
Low-Grade Neuroepithelial Tumor, NOS +
KRAS is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Lung Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Colorectal Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for malignant colorectal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant colorectal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Esophagogastric Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Malignant Female Reproductive System Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Gastric Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and malignant gastric neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Malignant Intestinal Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Malignant Ovarian Epithelial Tumor +
KRAS is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Peripheral Nerve Sheath Tumor +
KRAS is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Small Intestinal Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Malignant Testicular Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for malignant testicular neoplasm, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and malignant testicular neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Mantle Cell Lymphoma +
KRAS is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].
Mesothelioma +
KRAS is an inclusion criterion in 1 clinical trial for mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].
Mucosal Melanoma +
KRAS is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
KRAS is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].
Myeloid Neoplasm +
KRAS is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Neuroblastoma +
KRAS is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Neuronal And Mixed Neuronal-Glial Tumors +
KRAS is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Papillary Renal Cell Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Peripheral T-Cell Lymphoma +
KRAS is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].
Peritoneal Mesothelioma +
KRAS is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].
Pilocytic Astrocytoma +
KRAS is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Pilomyxoid Astrocytoma +
KRAS is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Pleural Mesothelioma +
KRAS is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [4].
Primary Peritoneal Low Grade Serous Adenocarcinoma +
KRAS is an inclusion criterion in 1 clinical trial for primary peritoneal low grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and primary peritoneal low grade serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Rectal Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for rectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and rectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Refractory Anemia With Excess Blasts +
KRAS is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (0 open) [4].
Rhabdoid Tumor +
KRAS is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Sarcoma +
KRAS is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Schwannoma +
KRAS is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Soft Tissue Sarcoma +
KRAS is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Squamous Cell Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].
T-Cell Acute Lymphoblastic Leukemia +
KRAS is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Therapy-Related Myelodysplastic Syndrome +
KRAS is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].
Thymic Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Follicular Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Thyroid Gland Papillary Carcinoma +
KRAS is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Uveal Melanoma +
KRAS is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and uveal melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
